High Priced Drugs

Germany drug pricing policies are now the subject of a US Section 301 investigation. AbbVie's chief counsel, Perry Siatis, has filed written evidence and testified that government price setting, mandatory rebates and reimbursement restrictions undercut the incentives that fund new medicines. He also cites a German-French working group on keeping innovative medicines available. #SyenzaNews #MarketAccess #DrugPricing #HEOR

Mounjaro passed €1 million in pharmacy sales in a single day in Portugal, on more than 3,000 packs, and the Ordem dos Médicos has asked Infarmed for prescription data. Here is what the numbers show on access, reimbursement and supply. #SyenzaNews #GLP1 #MarketAccess

South Africa has set a second single exit price adjustment for 2026, lifting listed medicine prices by 2.88% from 1 October. #SyenzaNews #MarketAccess #Pharma

Sandoz has put a date on its golden decade for biosimilars. The Bio100 plan targets more than 100 biosimilars by 2040, about 80% coverage of biosimilar-addressable LoE value from 2035, and a doubling of 2025 net sales. #SyenzaNews #MarketAccess #Biosimilars #ValueCreation

The United States has added nine more manufacturers to its most-favored-nation drug pricing program, taking the total to 26 companies that now cover 89% of the branded drug market. #MarketAccess #DrugPricing #Pharma

The Fifth Circuit affirmed the constitutionality of the Medicare drug price negotiation program, rejecting claims from NICA, the Global Colon Cancer Association, and PhRMA. #SyenzaNews #DrugPricing #MarketAccess #Pharma

South Africa’s health department pushes back on claims that state tenders are hollowing out pharmaceutical manufacturing, arguing the sector’s real pressures are regulatory rather than the result of procurement decisions.

🔑 How is South Africa’s SEP adjustment safeguarding pharma supply security? The latest Single Exit Price adjustment seeks to balance affordability with manufacturer sustainability, helping to stabilise medicine availability amid economic pressures. Read the full analysis to see what it means for pricing, supply chains and market access. #SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy

📉 Are prescription drug prices finally easing? A new analysis reveals a 3.1% decline, with potential ripple effects on market access, reimbursement strategies, and overall pharmaceutical economics. Read the full breakdown to see what it means for stakeholders. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #costeffectiveness

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

What does the FDA’s approval of ophthalmic bevacizumab mean for wet AMD patients? The agency has cleared a dedicated ophthalmic formulation, offering clinicians a targeted, cost-effective option to slow vision loss in one of the leading causes of blindness. Discover how this decision could reshape treatment pathways and market dynamics. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

🚀 Can regulatory reforms unlock Europe’s biotech edge? Streamlined approvals and reduced bureaucracy are at the heart of new EU proposals designed to attract investment and speed up innovation. See what these changes could mean for the sector. #SyenzaNews #biotechnology #regulatoryaffairs #innovation #MarketAccess